New pill targets Hard-to-Treat lung cancer mutation
NCT ID NCT07659782
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests an experimental daily pill, VS-7375, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. Participants must have already tried chemotherapy and an immunotherapy drug. The study looks at whether the drug can shrink tumors and how safe it is, both when used alone and with another cancer medicine.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VS-7375 (an oral KRAS G12D inhibitor)
What this could lead to
If successful, this could offer a new targeted treatment option for people with a specific type of advanced lung cancer that has not responded to prior therapies.
What could go wrong
This is an early-phase trial with a small number of participants. The drug may not shrink tumors or may cause side effects. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••